Valuation: AstraZeneca PLC

Market Cap 253B 225B 210B 191B 360B 24,346B 365B 2,541B 984B 12,399B 949B 929B 39,825B P/E 2026 *
20.8x
P/E 2027 * 18.1x
Enterprise Value 273B 242B 226B 206B 388B 26,242B 394B 2,739B 1,060B 13,365B 1,023B 1,001B 42,927B EV / Sales 2026 *
4.31x
EV / Sales 2027 * 3.95x
Free-Float
96.62%
Yield 2026 *
2.05%
Yield 2027 * 2.17%
1 day-2.33%
1 week-1.13%
1 month+2.39%
3 months-9.80%
6 months-11.98%
Current year-6.19%
1 week 135.71
Extreme 135.712
139.89
1 month 128.61
Extreme 128.614
139.89
Current year 124.91
Extreme 124.91
163
1 year 124.91
Extreme 124.91
163
3 years 104.86
Extreme 104.856
163
5 years 95
Extreme 95
163
10 years 52.7
Extreme 52.7
163
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-1.13% - - 253B
-0.77%-3.16%+38.66%+112.63% 1,031B
-1.85%-3.83%+39.91%+67.77% 638B
-0.74%-2.01%+6.31%+75.24% 462B
-0.84%-2.66%+59.82%+40.47% 359B
-0.03%-3.96%+23.63%+40.70% 335B
-1.58%-0.76%+13.50%+26.44% 273B
-2.02%-2.97%-3.25%+9.88% 253B
-2.77%+1.13%+37.56%+54.19% 228B
-0.99%-1.55%+32.59%+98.88% 185B
Average -1.39%-0.36%+27.64%+58.47% 418.21B
Weighted average by Cap. -1.25%-0.35%+30.57%+69.79%

Financials

2026 *2027 *
Net sales 63.17B 56.11B 52.47B 47.82B 90.02B 6,082B 91.26B 635B 246B 3,098B 237B 232B 9,949B 67.01B 59.52B 55.66B 50.72B 95.49B 6,452B 96.8B 673B 261B 3,286B 252B 246B 10,553B
Net income 12.04B 10.7B 10B 9.12B 17.16B 1,160B 17.4B 121B 46.85B 591B 45.22B 44.24B 1,897B 13.77B 12.23B 11.44B 10.43B 19.63B 1,326B 19.9B 138B 53.58B 675B 51.71B 50.59B 2,169B
Net Debt 19.69B 17.49B 16.36B 14.91B 28.06B 1,896B 28.45B 198B 76.61B 966B 73.94B 72.34B 3,102B 11.93B 10.6B 9.91B 9.03B 17B 1,149B 17.24B 120B 46.41B 585B 44.79B 43.82B 1,879B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
30/09/26 CHF 135.88 -2.33% 97
29/09/26 CHF 139.13 -0.05% 20
28/09/26 CHF 139.20 +0.40% 6
25/09/26 CHF 138.63 +1.04% 7
24/09/26 CHF 137.21 -0.17% 48
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
163.03USD
Average target price
210.47USD
Spread / Average Target
+29.10%

Quarterly revenue - Rate of surprise